Ozanimod - Celgene Corporation
Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIALatest Information Update: 26 May 2024
At a glance
- Originator The Scripps Research Institute
- Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
- Class Amines; Anti-inflammatories; Antivirals; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis; Ulcerative colitis
- Phase III Crohn's disease
- Phase II COVID 2019 infections
Most Recent Events
- 10 May 2024 Celgene plans a phase III trial for Multiple Sclerosis (In-children, In-adolescents, Treatment-experienced) in the USA (PO) (NCT06408259)
- 13 Apr 2024 Efficacy data from a phase III ENLIGHTEN trial in Multiple sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 29 Feb 2024 Updated efficacy data from a phase III ENLIGHTEN trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)